ESC Premium Access

PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Concluding discussion.

Topic: Valvular Heart Disease

Presentation

5 more presentations in this session

Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure - Pro.

Speaker: Associate Professor D. Sim (Singapore, SG)

Thumbnail

Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure- Contra.

Speaker: Professor J. Cleland (Glasgow, GB)

Thumbnail

Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure concluding discussion.

Thumbnail

PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Pro.

Speaker: Associate Professor M. Marwan (Erlangen, DE)

Thumbnail

PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Contra

Speaker: Associate Professor K. Sin (Singapore, SG)

Thumbnail

Access the full session

Controversies in 2019

Speakers: Associate Professor D. Sim, Professor J. Cleland, Associate Professor M. Marwan, Associate Professor K. Sin
Thumbnail

About the event

Image

ESC Asia with APSC & AFC

8 November - 10 November 2019

Sessions Presentations

This platform is supported by

logo Novo Nordisk